HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab

Co-expression of human epidermal growth factor receptor-2 (HER2) and hormone receptor (HR) predicted worse prognosis in early breast cancer before trastuzumab was developed. We aimed to investigate whether HER2 positivity was still associated with worse outcome in high-risk estrogen receptor (ER) po...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuai, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653101/
https://www.ncbi.nlm.nih.gov/pubmed/33166784
http://dx.doi.org/10.1016/j.breast.2020.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653101/
https://www.ncbi.nlm.nih.gov/pubmed/33166784
http://dx.doi.org/10.1016/j.breast.2020.10.002

Ejemplares similares